SAN CARLOS, Calif., Nov. 19, 2019 (GLOBE NEWSWIRE) — BioCardia®, Inc. [Nasdaq: BCDA], a leader in the development of comprehensive solutions for cardiovascular regenerative therapies, today reported financial results and business highlights for the third quarter 2019 and filed its quarterly report on Form 10-Q for the three and nine months ended […]
Other News
First Cryoballoon Ablation Procedures Performed Using the VersaCross® Transseptal Solution
TORONTO, Nov. 20, 2019 /PRNewswire/ – Baylis Medical announced today the first Arctic Front™ Advance Cryoballoon procedures performed using the VersaCross Transseptal Solution. The VersaCross solution is the world’s first all-in-one left-heart access device featuring an atraumatic RF-tipped wire, which acts as both puncture device and exchange rail. The puncture wire features […]
Haemonetics Releases TEG® 6s PlateletMapping® ADP & AA Assay Cartridge Globally
BRAINTREE, Mass., Nov. 20, 2019 /PRNewswire/ — Haemonetics Corporation (NYSE: HAE), a global medical technology company focused on delivering innovative hematology solutions to drive better patient outcomes, announced global commercial availability for the four-channel TEG® 6s PlateletMapping® ADP & AA assay cartridge. Intended for use with the TEG 6s Hemostasis Analyzer System, the cartridge is FDA […]
Highmark Health’s VITAL Innovation Platform is testing the benefits of Moving Analytics’ virtual cardiac rehabilitation program
VITAL platform will provide real-world evidence related to patient experience, health outcomes and cost impact PITTSBURGH, Nov. 20, 2019 /PRNewswire/ — Highmark Health announced today that through its VITAL Innovation Platform, it is testing Moving Analytics’ MOVN virtual cardiac rehabilitation solution for delivering cardiac rehab remotely to patients with heart disease. “In support of Highmark […]
MCRA Strengthens its Cardiovascular and Digital Health Franchise with Hiring Former FDA Assistant Director Nicole Goodsell Batista
WASHINGTON, Nov. 19, 2019 /PRNewswire/ — MCRA, LLC is a leading medical device advisory firm and clinical research organization (CRO) that integrates regulatory, clinical research, reimbursement, compliance and quality assurance in a coordinated manner to assist companies in bringing new technologies and products to the commercial market. We are pleased to announce the expansion […]
FDA Grants Breakthrough Device Designation Status for BioVentrix Revivent TC Transcatheter Ventricular Enhancement System for Heart Failure
SAN RAMON, Calif.–(BUSINESS WIRE)–BioVentrix, Inc., a privately-held company with a first-in-class, transcatheter-based structural heart device to treat heart failure, today announced that the U.S. Food and Drug Administration (FDA) has granted the company Breakthrough Device Designation status for its Revivent TC™ Transcatheter Ventricular Enhancement System for heart failure. Less Invasive […]
Prevencio Announces Highly Accurate, AI-driven Blood Test with High Sensitivity (hs) Cardiac Troponin for the Diagnosis of Heart Disease
HART CADhs test addresses up to 30% of Emergency Department (ED) chest pain patients who cannot safely be ruled-in nor ruled-out for heart attack KIRKLAND, Wash.–(BUSINESS WIRE)–Prevencio, Inc. today announces data confirming the high accuracy of its AI-driven, multiple-protein HART CADhs test, a biomarker clinical/proteomic panel inclusive of high sensitivity cardiac […]
Medtronic Reports Second Quarter Financial Results
Revenue of $7.7 Billion Increased 3.0% Reported and 4.1% Organic GAAP Diluted EPS of $1.01; Non-GAAP Diluted EPS of $1.31 Cash Flow from Operations of $1.9 Billion Grew 61%; Free Cash Flow of $1.6 Billion Grew 66% Company Raises FY20 EPS Guidance DUBLIN, Nov. 19, 2019 (GLOBE NEWSWIRE) — Medtronic plc […]
Neovasc Tiara™ Progress Highlighted at PCR London Valves 2019
VANCOUVER, Nov. 19, 2019 (GLOBE NEWSWIRE) — via NEWMEDIAWIRE — Neovasc, Inc. (“Neovasc” or the “Company”) (NASDAQ, TSX: NVCN), a leader in the development of minimally invasive transcatheter mitral valve replacement technologies and in the development of minimally invasive devices for the treatment of refractory angina, announced that its transfemoral trans-septal (“TF/TS”) Tiara™ […]
Amarin Highlights Key REDUCE-IT®-Related Data Presented at American Heart Association 2019 Scientific Sessions
REDUCE-IT USA results, in prespecified subgroup analyses, showed cardiovascular risk reductions across all endpoints, including 30% relative risk reduction in all-cause mortality New analysis determined icosapent ethyl (Vascepa®) is highly cost-effective in patients from the REDUCE-IT study and, as is rarely found, may result in net healthcare cost-savings to patients, payers […]
